Colorectal Cancer Cell and Gene Therapy Market Size and Trend Report including Epidemiology, Disease Management, Pipeline Analysis, Competitor Assessment, Unmet Needs and Forecast, 2031

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Colorectal Cancer Market Report Overview

The Colorectal Cancer (CRC) 15 (CGT and established/conventional therapies) market size was $18.9 billion in 2021. CRC has one of the largest gene therapy/oncolytic virus clinical pipelines across all of oncology, and a relatively active clinical cell therapy pipeline compared to other solid tumors. There are currently no marketed or Phase III CGT agents in CRC, reflecting the difficulties of progressing these drug types into the CRC market. This is largely due to insufficient efficacy; however, there is high clinical potential for a CGT agent that shows long-term disease control in metastatic CRC.

Colorectal Cancer Market Outlook, 2021-2031 ($ Billion)

CRC Market Outlook

For more insights into the Colorectal Cancer market forecast, download a free report sample

The Colorectal Cancer (CRC) market research report includes an assessment of the disease epidemiology and 10-year patient-based forecast (PBF) across the 8MM for marketed and pipeline therapies with established mechanisms of action and cell therapies by class, including early to late clinical-stage pipeline products, with a launch date assessment by market for colorectal cancer (CRC).

Market Size (2021) $18.9 billion
Key Regions APAC, Europe, Middle East, and North America
Leading Companies Turnstone Biologics Inc., Alaunos Therapeutics Inc, F-Hoffmann-La Roche Ltd, Immunovative Therapies Ltd, Zhejiang Yangshengtang Biotech Co Ltd, Replimune Ltd, University of Texas MD Anderson Cancer Center, Bristol-Myers Squibb Co, Iovance Biotherapeutics, and Transgene SA

CRC Market Drivers

The key market drivers include-

  • Combination therapy of OVs + ICIs in dMMR/MSI-H patients in 2L and 3L settings
  • Suboptimal survival and lack of available treatment options for mCRC patients in 3L+ settings driving CGT usage
  • Large eligible patient population sizes for cell therapies targeting EGFR

CRC Market- Unmet Needs

The unmet need for mCRC remains high, with the greatest unmet need within mCRC being the lack of treatment options for RAS-mutated patients, which make up a large proportion of the total mCRC patient population. Most patients with mCRC experience disease progression or develop resistance to the currently available treatment options, therefore the most clinically valuable way for CGT agents to add value is by demonstrating durable long-term remission. However, gene therapy and oncolytic viruses do not easily lend themselves to meeting this unmet need and may be more suitable to improving outcomes in dMMR/MSI-H patients due to these patients having more immunogenic tumors, and long-term data for patients treated with cell therapies remains to be generated.

CRC Market Segmentation by Region

The key regions in the CRC market are APAC, Europe, Middle East, and North America. In 2021, North America is the leading region in the CRC market. GlobalData expects that the North American thyroid function tests market will grow during the forecast period, primarily due to increases in the prevalence of hyperthyroidism and hypothyroidism, as well as greater public awareness of these diseases. Change in diet, lifestyle, and aging populations are driving the number of thyroid disease cases and thus test sales.

Colorectal Cancer Market Analysis by Region, 2021 (%)

CRC Market Analysis, by Region

For more regional insights into the Colorectal Cancer market, download a free report sample

CRC Market- Competitive Landscape and Future Players Based on Pipeline Strength

Some of the future players by number of ongoing clinical trials and development phase are Turnstone Biologics Inc., Alaunos Therapeutics Inc, F-Hoffmann-La Roche Ltd, Immunovative Therapies Ltd, Zhejiang Yangshengtang Biotech Co Ltd, Replimune Ltd, University of Texas MD Anderson Cancer Center, Bristol-Myers Squibb Co, Iovance Biotherapeutics, and Transgene SA. Many of the top 10 pharma companies are looking to enter the CGT space in CRC. The clinical pipeline for CGT agents in CRC is dispersed over many different companies, largely consisting of small-medium sized US or China-based biotechs and large global pharma companies. Cell therapy presents as the most advanced CGT modality, with three ongoing Phase II trials sponsored by Immunovative Therapies, Bristol-Myers Squibb, and ImmunityBio. Unlike in hematological malignancies, approvals based on Phase II data are highly unlikely in CRC, therefore the future players will be better elucidated when Phase III trials have been initiated.

Scope

This report includes disease epidemiology, a 10-year patient-based forecast for marketed and pipeline therapies with established mechanisms of action and cell & gene therapies by class, including early- to late clinical-stage pipeline products with launch date assessment by 8MM market.

Key Highlights

  • Report deliverables include a PowerPoint report and an Excel-based forecast model
  • Forecast includes 8 countries
  • Forecast covers 2021-2031
  • Seven markets are extrapolated, obtaining a 15-market value for all CRC therapeutics

Reasons to Buy

  • Obtain cell & gene therapy sales forecasts across multiple regions
  • Gain insight into promising early-stage approaches

Astellas
Alaunos Therapeutics
Replimune
Triumvira Immunologics

Table of Contents

Table of Contents (PowerPoint Deck)

1. Preface

1.1. Contents

1.2. Report Scope

2. Executive Summary

3. Disease Overview

3.1. Etiology & Epidemiology

3.2. CRC Treatment Algorithm

4. Pipeline Drugs Overview

4.1. Pipeline Analysis

4.2. Target Analysis and Clinical Benchmarks

5. Market Outlook

5.1. 10-Year Market Analysis with Drivers and Barriers

6. Unmet Needs

7. Likelihood of Approval Analysis and Phase Transition Success Rate Analysis

8. Competitive Assessment

8.1. Competitive Analysis by Class of Therapy

9. Future Players and Catalyst

9.1. Future Players Based on Pipeline Strength

10. Appendix

10.1. Cell & Gene Therapies Forecast Methodology Overview

10.2. Pricing of Cell & Gene Therapies

10.3. Pipeline Launch Assumptions

10.4. Abbreviations and Definitions

10.5. Methodology

10.6. About the Authors

11. Contact Us

Frequently asked questions

Colorectal Cancer Cell and Gene Therapy Market Size and Trend Report including Epidemiology, Disease Management, Pipeline Analysis, Competitor Assessment, Unmet Needs and Forecast, 2031 thematic reports
Currency USD
$9,995

Can be used by individual purchaser only

$29,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Colorectal Cancer Cell and Gene Therapy Market Size and Trend Report including Epidemiology, Disease Management, Pipeline Analysis, Competitor Assessment, Unmet Needs and Forecast, 2031 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Colorectal Cancer Cell and Gene Therapy Market Size and Trend Report including Epidemiology, Disease Management, Pipeline Analysis, Competitor Assessment, Unmet Needs and Forecast, 2031 in real time.

  • Access a live Colorectal Cancer Cell and Gene Therapy Market Size and Trend Report including Epidemiology, Disease Management, Pipeline Analysis, Competitor Assessment, Unmet Needs and Forecast, 2031 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.